- Home
- IFRX vs THCH Comparison
IFRX vs THCH Comparison
Compare IFRX & THCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- THCH
- Stock Information
- Founded
- IFRX 2007
- THCH 2018
- Country
- IFRX Germany
- THCH China
- Employees
- IFRX N/A
- THCH N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- THCH Blank Checks
- Sector
- IFRX Health Care
- THCH Finance
- Exchange
- IFRX Nasdaq
- THCH Nasdaq
- Market Cap
- IFRX 117.8M
- THCH 141.1M
- IPO Year
- IFRX 2017
- THCH N/A
- Fundamental
- Price
- IFRX $1.15
- THCH $3.02
- Analyst Decision
- IFRX Strong Buy
- THCH
- Analyst Count
- IFRX 2
- THCH 0
- Target Price
- IFRX $9.00
- THCH N/A
- AVG Volume (30 Days)
- IFRX 337.7K
- THCH 14.3K
- Earning Date
- IFRX 05-07-2025
- THCH 04-17-2025
- Dividend Yield
- IFRX N/A
- THCH N/A
- EPS Growth
- IFRX N/A
- THCH N/A
- EPS
- IFRX N/A
- THCH N/A
- Revenue
- IFRX $171,642.00
- THCH $207,029,179.00
- Revenue This Year
- IFRX $106.72
- THCH N/A
- Revenue Next Year
- IFRX $66.89
- THCH N/A
- P/E Ratio
- IFRX N/A
- THCH N/A
- Revenue Growth
- IFRX 162.79
- THCH N/A
- 52 Week Low
- IFRX $1.01
- THCH $2.78
- 52 Week High
- IFRX $2.82
- THCH $7.20
- Technical
- Relative Strength Index (RSI)
- IFRX 38.70
- THCH 47.35
- Support Level
- IFRX $1.01
- THCH $2.84
- Resistance Level
- IFRX $1.30
- THCH $3.05
- Average True Range (ATR)
- IFRX 0.13
- THCH 0.23
- MACD
- IFRX 0.02
- THCH -0.01
- Stochastic Oscillator
- IFRX 34.15
- THCH 33.33
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.